CN104412270A - 自动确定抗癌候选药物的相对有效性的系统和方法 - Google Patents
自动确定抗癌候选药物的相对有效性的系统和方法 Download PDFInfo
- Publication number
- CN104412270A CN104412270A CN201380035279.0A CN201380035279A CN104412270A CN 104412270 A CN104412270 A CN 104412270A CN 201380035279 A CN201380035279 A CN 201380035279A CN 104412270 A CN104412270 A CN 104412270A
- Authority
- CN
- China
- Prior art keywords
- drug
- option
- test
- interface
- drug candidate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 39
- 229940125648 antineoplastic drug candidate Drugs 0.000 title description 8
- 229940000406 drug candidate Drugs 0.000 claims abstract description 90
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 65
- 201000011510 cancer Diseases 0.000 claims abstract description 59
- 230000006907 apoptotic process Effects 0.000 claims abstract description 38
- 238000003255 drug test Methods 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 35
- 230000003287 optical effect Effects 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims description 102
- 229940079593 drug Drugs 0.000 claims description 44
- 238000004891 communication Methods 0.000 claims description 24
- 230000001640 apoptogenic effect Effects 0.000 claims description 20
- 238000011275 oncology therapy Methods 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 11
- 238000010586 diagram Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 abstract description 194
- 238000005259 measurement Methods 0.000 abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 124
- 230000008569 process Effects 0.000 description 17
- 230000008859 change Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 238000007726 management method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000037452 priming Effects 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 101150051290 BLNK gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/59—Transmissivity
- G01N21/5907—Densitometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Computing Systems (AREA)
- Theoretical Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Software Systems (AREA)
- Databases & Information Systems (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
Claims (42)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261641610P | 2012-05-02 | 2012-05-02 | |
US61/641,610 | 2012-05-02 | ||
US13/803,623 | 2013-03-14 | ||
US13/803,623 US9476871B2 (en) | 2012-05-02 | 2013-03-14 | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
PCT/US2013/039189 WO2013166233A1 (en) | 2012-05-02 | 2013-05-02 | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104412270A true CN104412270A (zh) | 2015-03-11 |
CN104412270B CN104412270B (zh) | 2018-03-20 |
Family
ID=49514877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380035279.0A Expired - Fee Related CN104412270B (zh) | 2012-05-02 | 2013-05-02 | 自动确定抗癌候选药物的相对有效性的系统和方法 |
Country Status (23)
Country | Link |
---|---|
US (3) | US9476871B2 (zh) |
EP (2) | EP4134962A1 (zh) |
JP (1) | JP6365988B2 (zh) |
KR (1) | KR102028711B1 (zh) |
CN (1) | CN104412270B (zh) |
AU (2) | AU2013256248B2 (zh) |
BR (1) | BR112014027287A2 (zh) |
CA (1) | CA2872109C (zh) |
CL (1) | CL2014002981A1 (zh) |
CO (1) | CO7190233A2 (zh) |
CR (1) | CR20140551A (zh) |
CU (1) | CU20140125A7 (zh) |
HK (1) | HK1203670A1 (zh) |
IL (1) | IL235455B (zh) |
MX (1) | MX345540B (zh) |
NI (1) | NI201400128A (zh) |
NZ (1) | NZ702526A (zh) |
PE (1) | PE20150299A1 (zh) |
PH (1) | PH12014502687A1 (zh) |
RU (1) | RU2014148543A (zh) |
SG (1) | SG11201407141VA (zh) |
TW (1) | TWI605413B (zh) |
WO (1) | WO2013166233A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109074860A (zh) * | 2016-04-18 | 2018-12-21 | 富士胶片株式会社 | 代替医药品检索装置及代替医药品检索方法 |
CN110047562A (zh) * | 2019-05-14 | 2019-07-23 | 上海上药第一生化药业有限公司 | 一种基于酶活力测定法的效价检测的信息化结构和方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9476871B2 (en) * | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
KR20150035537A (ko) * | 2012-05-15 | 2015-04-06 | 디아테크 온콜로지, 엘엘씨 | 종양 세포 분리/정제 프로세스 및 이의 사용 방법들 |
US9460407B2 (en) * | 2013-05-03 | 2016-10-04 | Sap Se | Generating graphical representations of data |
WO2015171848A2 (en) * | 2014-05-08 | 2015-11-12 | Diatech Oncology, Llc | Synergism and antagonism between multiple anti-cancer agents determined by mick assay |
US11151604B2 (en) * | 2016-06-10 | 2021-10-19 | International Business Machines Corporation | Revenue management using dynamic customer selection |
US20200388355A1 (en) * | 2019-06-07 | 2020-12-10 | Cary A. Presant | Method and devices for direct apoptosis assay of purified cells |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1220395A (zh) * | 1997-12-15 | 1999-06-23 | 中国科学院生物物理研究所 | 一种基于微量元素分布特征的抗癌药物筛选方法 |
WO2002040702A2 (en) * | 2000-11-09 | 2002-05-23 | Vanderbilt University | Methods for the treatment of cancer and other diseases and methods of developing the same |
CN1954887A (zh) * | 2005-10-28 | 2007-05-02 | 中国科学院大连化学物理研究所 | 一种体外抗癌药物筛选模型的制备方法 |
US20090221436A1 (en) * | 2000-11-17 | 2009-09-03 | Slanetz Alfred E | Process for determining target function and identifying drug leads |
US20110244503A1 (en) * | 2010-03-31 | 2011-10-06 | Perree Mathieu | System and Method for Anti-Cancer Drug Candidate Evaluation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5068181A (en) | 1989-12-01 | 1991-11-26 | Akzo N.V. | Method of monitoring reagent delivery in a scanning spectrophotometer |
US5356793A (en) | 1990-03-15 | 1994-10-18 | Nitta Gelatin Inc. | Method for testing the sensitivity of anticancer drug |
US6077684A (en) | 1996-11-14 | 2000-06-20 | Vanderbilt University | Automated assay for measuring apoptosis in cell culture |
US6448030B1 (en) | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
WO2002046750A2 (en) | 2000-11-13 | 2002-06-13 | Vanderbilt University | Methods of predicting chemotherapy response |
EP1483401A1 (en) | 2002-03-13 | 2004-12-08 | F.Hoffmann-La Roche Ag | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
US6900058B2 (en) | 2003-03-11 | 2005-05-31 | Bionostics, Inc. | Control solution for photometric analysis |
EP1872139A2 (en) * | 2005-04-09 | 2008-01-02 | Cell Biosciences, Inc. | Automated micro-volume assay system |
US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
KR100721927B1 (ko) | 2006-10-31 | 2007-05-28 | 이수앱지스 주식회사 | 암조직에서 암세포를 분리하는 방법 |
WO2010006303A2 (en) | 2008-07-10 | 2010-01-14 | Nodality, Inc. | Methods and apparatus related to management of experiments |
US20120224053A1 (en) * | 2009-06-17 | 2012-09-06 | Board Of Regents, The University Of Texas System | Method and apparatus for quantitative microimaging |
KR101533469B1 (ko) | 2010-02-03 | 2015-07-02 | 연세대학교 산학협력단 | Ras의 Thr-144번과 Thr-148번의 인산화의 감지를 통한 암 진단 방법, 항암제 스크리닝 및 약효테스트 방법 |
US8475739B2 (en) * | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
US9476871B2 (en) * | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
KR20150035537A (ko) | 2012-05-15 | 2015-04-06 | 디아테크 온콜로지, 엘엘씨 | 종양 세포 분리/정제 프로세스 및 이의 사용 방법들 |
-
2013
- 2013-03-14 US US13/803,623 patent/US9476871B2/en active Active
- 2013-04-30 TW TW102115445A patent/TWI605413B/zh active
- 2013-05-02 AU AU2013256248A patent/AU2013256248B2/en not_active Ceased
- 2013-05-02 MX MX2014013271A patent/MX345540B/es active IP Right Grant
- 2013-05-02 PE PE2014001938A patent/PE20150299A1/es not_active Application Discontinuation
- 2013-05-02 CN CN201380035279.0A patent/CN104412270B/zh not_active Expired - Fee Related
- 2013-05-02 WO PCT/US2013/039189 patent/WO2013166233A1/en active Application Filing
- 2013-05-02 NZ NZ702526A patent/NZ702526A/en not_active IP Right Cessation
- 2013-05-02 CA CA2872109A patent/CA2872109C/en active Active
- 2013-05-02 SG SG11201407141VA patent/SG11201407141VA/en unknown
- 2013-05-02 BR BR112014027287A patent/BR112014027287A2/pt not_active Application Discontinuation
- 2013-05-02 JP JP2015510444A patent/JP6365988B2/ja active Active
- 2013-05-02 KR KR1020147033937A patent/KR102028711B1/ko active IP Right Grant
- 2013-05-02 EP EP22180904.9A patent/EP4134962A1/en not_active Withdrawn
- 2013-05-02 EP EP13784507.9A patent/EP2847701A4/en not_active Ceased
- 2013-05-02 RU RU2014148543A patent/RU2014148543A/ru not_active Application Discontinuation
-
2014
- 2014-10-31 NI NI201400128A patent/NI201400128A/es unknown
- 2014-11-02 IL IL235455A patent/IL235455B/en not_active IP Right Cessation
- 2014-11-03 CU CU2014000125A patent/CU20140125A7/es unknown
- 2014-11-03 CL CL2014002981A patent/CL2014002981A1/es unknown
- 2014-12-02 CO CO14265404A patent/CO7190233A2/es unknown
- 2014-12-02 PH PH12014502687A patent/PH12014502687A1/en unknown
- 2014-12-02 CR CR20140551A patent/CR20140551A/es unknown
-
2015
- 2015-05-04 HK HK15104231.4A patent/HK1203670A1/zh unknown
-
2016
- 2016-10-04 US US15/285,292 patent/US10488402B2/en active Active
-
2018
- 2018-12-21 AU AU2018282460A patent/AU2018282460B2/en active Active
-
2019
- 2019-10-02 US US16/591,389 patent/US12066427B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1220395A (zh) * | 1997-12-15 | 1999-06-23 | 中国科学院生物物理研究所 | 一种基于微量元素分布特征的抗癌药物筛选方法 |
WO2002040702A2 (en) * | 2000-11-09 | 2002-05-23 | Vanderbilt University | Methods for the treatment of cancer and other diseases and methods of developing the same |
US20090221436A1 (en) * | 2000-11-17 | 2009-09-03 | Slanetz Alfred E | Process for determining target function and identifying drug leads |
CN1954887A (zh) * | 2005-10-28 | 2007-05-02 | 中国科学院大连化学物理研究所 | 一种体外抗癌药物筛选模型的制备方法 |
US20110244503A1 (en) * | 2010-03-31 | 2011-10-06 | Perree Mathieu | System and Method for Anti-Cancer Drug Candidate Evaluation |
Non-Patent Citations (1)
Title |
---|
VLADIMIR D.KRAVTSOV ET AL.: "Use of Microculture Kinetic Assay of Apoptosis to Determine Chemosensitivities of Leukemias", 《BLOOD》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109074860A (zh) * | 2016-04-18 | 2018-12-21 | 富士胶片株式会社 | 代替医药品检索装置及代替医药品检索方法 |
CN110047562A (zh) * | 2019-05-14 | 2019-07-23 | 上海上药第一生化药业有限公司 | 一种基于酶活力测定法的效价检测的信息化结构和方法 |
CN110047562B (zh) * | 2019-05-14 | 2021-04-27 | 上海上药第一生化药业有限公司 | 一种基于酶活力测定法的效价检测的信息化结构和方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104412270A (zh) | 自动确定抗癌候选药物的相对有效性的系统和方法 | |
Yuan et al. | Bayesian designs for phase I-II clinical trials | |
US10262107B1 (en) | Pharmacogenetic drug interaction management system | |
Browning et al. | Quantitative analysis of tumour spheroid structure | |
US9792548B2 (en) | Systems and methods for biochemical data analysis | |
Dash et al. | Biospecimens and biorepositories for the community pathologist | |
Mroczek et al. | Data overuse in aging research: Emerging issues and potential solutions. | |
Bussola et al. | A weakly supervised deep learning framework for whole slide classification to facilitate digital pathology in animal study | |
Tarling et al. | The availability of human biospecimens to support biomarker research | |
Schweizer et al. | Enhancing cancer drug discovery through novel cell signaling pathway panel strategy | |
Sego et al. | Unification of aggregate growth models by emergence from cellular and intracellular mechanisms | |
D’Abbronzo et al. | The changing role of the pathologist in the era of targeted therapy in personalized medicine | |
JP2012078934A (ja) | 化学物質毒性試験の帳票出力システム及び帳票出力方法並びに帳票出力プログラム | |
Rogers et al. | Making Complex Cancer Reports Easier Using Self-Built Interactive Templates | |
Knijn et al. | Guidelines for reporting histopathology studies | |
Schweizer et al. | Constructing tissue microarrays for research use | |
Faratian et al. | Dynamic Computational Modeling in the Searchf For Better Breast Cancer Drug Therapy | |
Opasic | Sampling Strategies in Evolving Cancer: From Mathematical Models to Clinical Application | |
Opašić | Sampling Strategies in Evolving Cancer | |
Zink | Software development for the use of a mathematical prediction tool for chemotherapy responsiveness in a clinical and in a research environment | |
Gul et al. | PS2-39: Key Challenges and Decisions in the Development of HMO Death Data | |
JONES | CANADA’S MICHAEL SMITH GENOME SCIENCES CENTRE | |
Meenakshi et al. | Big Data in Drug Discovery, Development, and Pharmaceutical Care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1203670 Country of ref document: HK |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Tennessee Applicant after: DiaTech Oncology LLC Address before: Tennessee Applicant before: Diya technology Co. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171122 Address after: Tennessee Applicant after: Diya technology Co. Address before: Tennessee Applicant before: DIATECH ONCOLOGY |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180320 Termination date: 20190502 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1203670 Country of ref document: HK |